Navigation Links
JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
Date:6/20/2013

NEW YORK, June 20, 2013 /PRNewswire-USNewswire/ -- JDRF announced today partnerships with both Xeris Pharmaceuticals, Inc., and LATITUDE Pharmaceuticals, Inc. (LPI), to support the development soluble glucagon formulations—an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).

First-generation artificial pancreas systems currently being tested in JDRF-supported outpatient clinical trials use technologies already available; they combine a continuous glucose monitor (CGM) with an insulin pump using computer software, to partially automate the right amount of insulin delivery at the right times for people with T1D.

"Studies have demonstrated the game-changing value of first generation artificial pancreas systems in improving blood-glucose control and alleviating some of the burdens of managing type 1 diabetes," said Sanjoy Dutta, Ph.D., JDRF's senior director of treat therapies. "Still, future generation artificial pancreas systems are expected to do even more. To become fully automated, closed loop systems, new technologies and drugs—including stable, pumpable glucagon—will be required in order to more closely and accurately mimic the functions of a healthy pancreas. Both near-term and long-term projects to advance the artificial pancreas are important research priorities for JDRF."

While first-generation artificial pancreas systems will deliver insulin, one of the aspects of future generations will be their ability to deliver multiple hormones, such as glucagon. Glucagon is a naturally occurring hormone that raises blood-sugar levels to prevent hypoglycemia (low blood sugar), but its regulation is impaired in people with T1D, for whom hypoglycemia can be dangerous. In a healthy pancreas, it complements the function of insulin to provide the natural fine-tuning of blood-glucose control, and previous studies supported by JDRF and others have shown that the addition of glucagon to insulin treatment in T1D reduces the frequency of hypoglycemia.

One major hurdle in developing an advanced generation, multi-hormonal artificial pancreas system is that commercially available glucagon does not remain stable; the powder and solution mix into a short-lived liquid form not suitable for long-term use in a pump. Xeris and LPI will develop two different approaches to making glucagon usable for infusion pumps.

Xeris—a specialty pharmaceutical company based in Austin, TX, focused on developing injectable therapeutics—will study its stable, room-temperature, and non-aqueous injectable glucagon (G-Pump™ Glucagon) to treat hypoglycemia. Clinical studies will take place at Oregon Health & Science University (OHSU) with two years of milestone-based funding from JDRF.

"Our partnership with JDRF enables us to move forward in pursuing an improved approach to controlling blood glucose levels  by enabling a fully closed loop system that addresses  both hyperglycemia and hypoglycemia," said Steve Prestrelski, Ph.D., chief executive officer at Xeris. "We look forward to working with JDRF to make this a successful program."

LPI—a drug formulation development company based in San Diego, CA—will use a unique, proprietary, solvent-free, glucagon nanoemulsion (Nano-G) to solubilize and stabilize the molecule, such that it is not vulnerable to degradation and remains biologically active. With milestone-based funding from JDRF for one year, LPI plans to begin clinical testing in the United States in 2014.

"LATITUDE is truly honored to partner with a prestigious and leading organization such as JDRF," said Andrew Chen, Ph.D., LPI's president. "This partnership will accelerate LATITUDE's stable, soluble glucagon formulation and its potential for new medical applications. Our partnership with JDRF will give us an opportunity to provide a missing piece needed to make the bi-hormonal artificial pancreas a reality."

Both Xeris and LPI are using approaches distinct from the ongoing JDRF-supported research program led by W. Kenneth Ward, M.D. at OHSU, which is utilizing a liquid solution of glucagon at a high pH in order to stabilize the drug.

Said Dr. Dutta: "We are excited to explore whether the novel glucagon formulations by Xeris and LATITUDE could prove effective for use in an infusion pump, thereby bringing us closer to the future of closed loop artificial pancreas systems by 'resetting' the missing hormonal balance in people with type 1 diabetes."

About T1D
In T1D, a person's pancreas stops producing insulin, a hormone that enables people to get energy from food. People with T1D need to test their blood sugar and give themselves insulin (with injections or an insulin pump) multiple times every day, and carefully balance insulin doses with eating and daily activities throughout the day and night. However, insulin is not a cure for diabetes, and even with that intensive care, a significant portion of the day is still spent with either high or low blood sugar, placing people with T1D at risk for devastating complications such as heart attack, stroke, blindness, and amputation.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness.

For more information, please visit jdrf.org.

About Xeris Pharmaceuticals, Inc.
Xeris is a specialty pharmaceutical company based in Austin, Texas focused on improving injectable therapeutics by eliminating reconstitution, simplifying administration, and easing the pain of injections for patients and caregivers. In the diabetes space, Xeris is developing a stable, non-aqueous, injectable glucagon for the treatment of hypoglycemia. The company has developed a room-temperature stable formulation which is being leveraged for multiple opportunities ranging from a rescue pen (the G-Pen™) for treatment of severe hypoglycemia, to a pump-based formulation (G-Pump™ Glucagon) for use in a bi-hormonal artificial pancreas.

About LATITUDE Pharmaceuticals, Inc.
LPI is a leading drug formulation development group that incorporates innovative and leading-edge approaches into its client projects and into its own reformulation programs. The company is recognized for its success with highly insoluble drugs and for developing inventive approaches and intellectual property for its clients. LPI's internal programs focus on developing outlicense-ready 505(b)(2) NDA opportunities.


'/>"/>
SOURCE JDRF
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
2. Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option
3. Haemonetics Announces Next Steps in Manufacturing Transformation
4. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
5. BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research
6. Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital
7. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
8. Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
9. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Specialty Coating Systems Announces New Antimicrobial Parylene Technology
11. Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):